

## LOCAL COST STUDY OF TREATMENT OF VENOUS THROMBOEMBOLISM IN TURKEY

Tatar M.<sup>1</sup>, Senturk A.<sup>2</sup>, Tuna E.<sup>2</sup>, Bilginer B.<sup>3</sup>, Ulus A.T.<sup>3</sup>, Poyraz B.M.<sup>4</sup>, Buyuktuna N.<sup>5</sup>, Hacibedel B.<sup>6</sup>

<sup>1</sup>Hacettepe University, Ankara, Turkey, <sup>2</sup>Polar Saglik Health Economics & Policy, Ankara, Turkey, <sup>3</sup>Hacettepe University Hospital, Ankara, Turkey, <sup>4</sup>TOBB ETU Hospital, Ankara, Turkey, <sup>5</sup>Bristol Myers Squibb, Turkey, Istanbul, Turkey, <sup>6</sup>Pfizer Turkey, Istanbul, Turkey

### BACKGROUND AND AIM

Venous thromboembolism (VTE) is a common disorder, with about 1 per 1,000 people per year in general population. Around two thirds of the cases are deep vein thrombosis (DVT) and one third are pulmonary embolism (PE). PE can cause sudden death or intensive use of health care resources. The clinical course of DVT may also be complicated by recurrent episodes of DVT, the development of post-thrombotic syndrome (PTS), as well as chronic thromboembolic pulmonary hypertension (CTEPH). The aim of this study was to estimate the cost of VTE treatment in Turkey.

### METHODS AND RESULTS

The study was undertaken from the Turkish health care payer perspective. (Social Security Institution-SSI). As Turkey does not have publicly available resource utilization data, expert views are frequently referred to estimate treatment costs. An Excel sheet was formed to determine the healthcare resources used in treatment of VTE. Table 1 presents an example for monitoring of intracranial bleeding. VTE treatment costs were divided by anticoagulant use, INR monitoring, recurrent DVT, recurrent PE, Non-Intracranial major bleeding (GIS), Intracranial bleed, CTEPH and PTS long term costs. Unit costs were taken from the Social Security Institution's Health Implementation Guideline. The results are presented in Table 2.

**Table 1:** Resource Use and Costs in Intracranial Bleeding

Resources	Unit	Unit Cost (TL)	Patients (%)	Frequency	Total Cost (TL)
Dr. Visit	1 visit	15.50	100	5	207.50*
Diph.Hid.	100 mg kps	0.07	100	3	76.65
CT	Once	55.00	100	1	55.00
Diph Hid Level	Once	18.00	2	1	*
Blood Biochem.	Once	19.20	2	1	*
Total					<b>339.15</b>

\*Package price

**Table 2:** Local Costs of Treatment of VT in Turkey

LOCAL COSTS	TL
Anticoagulant use	146.59
Monitoring INR	90.00
Recurrent DVT	1,9072.41
Recurrent PE	830.49
Non IC major bleeding (GIS)	1,482.49
CRNM bleed	Ignored
Intracranial bleed	3,868.86
CTEPH	22,228.12
PTS long term	754.29

### CONCLUSIONS

The study showed that VTE treatment poses a high treatment cost in the Turkish health care system.

\* This study was supported by Bristol Myers Squibb and Pfizer